Every 67 seconds, someone in the United States develops Alzheimer’s disease. By April 2026, roughly 7 million Americans aged 65 and older are living with the condition, according to estimates drawn from the CDC’s national dementia data and the Alzheimer’s Association’s annual Facts and Figures report. Federal health officials warn that number will climb sharply as baby boomers age deeper into their 70s and 80s, potentially approaching 13 million by midcentury.
But doctors and researchers are pushing back against the notion that cognitive decline is inevitable. A growing body of clinical evidence shows that many of the forces driving dementia risk, from uncontrolled blood pressure to physical inactivity, are factors people can actually change. The challenge now is closing the gap between what science has established and what most Americans do about it.
The risk factors people can control
The strongest evidence centers on cardiovascular health. The SPRINT MIND trial, a landmark randomized controlled study published in JAMA, found that intensive blood pressure management slowed certain forms of cognitive decline in adults over 50. That finding gave clinicians one of their clearest tools yet: treating hypertension aggressively does not just protect the heart. It protects the brain.
The National Institute on Aging’s guidance on cognitive health builds on that foundation. The agency recommends regular physical activity, careful management of diabetes and high cholesterol, sustained social engagement, and hearing protection as evidence-backed strategies. None of these are speculative. Each is supported by large population studies or clinical trials.
A 2024 Lancet Commission report reinforced the case on a global scale. An international panel of researchers identified 14 modifiable risk factors for dementia, including hearing loss, hypertension, social isolation, limited education, and physical inactivity. The commission estimated that addressing these factors across a person’s lifetime could prevent or delay a significant share of dementia cases worldwide. “This is not about one magic intervention,” the report’s framing suggests. “It is about sustained, layered prevention starting as early as possible.”
What new treatments can and cannot do
The past few years have brought the first disease-modifying drugs for Alzheimer’s to market. Lecanemab (sold as Leqembi) received full FDA approval in 2023, and donanemab (Kisunla) followed in 2024. Both are anti-amyloid antibodies designed to slow progression in people with early-stage Alzheimer’s by clearing toxic protein plaques from the brain.
These drugs represent genuine scientific progress, but they are not cures. Clinical trials showed modest slowing of cognitive decline, and both carry serious risks, including brain swelling and microbleeds. They require regular infusions, PET scans or spinal taps for eligibility confirmation, and close monitoring. Access remains uneven: many community hospitals lack the infrastructure to administer them, and out-of-pocket costs can be steep even with Medicare coverage.
That reality makes prevention strategies all the more urgent. Drugs that slow the disease by a few months are valuable, but they do not replace the broader public health goal of reducing how many people develop Alzheimer’s in the first place.
Where the science is still catching up
For all the progress on risk factors, several important questions remain open. The Lancet Commission’s framework draws heavily on global data, and researchers have not yet confirmed through large domestic longitudinal studies how well its estimates apply to specific U.S. populations, particularly communities with unequal access to education, hearing care, or cardiovascular treatment.
Dietary supplements are another area where consumer interest far outpaces the evidence. The NIA notes that research on nutritional interventions is mixed, and no major U.S. clinical trial has produced a clear winner among the vitamins, fish oils, or herbal products most commonly marketed for brain health. Federal agencies have not endorsed any supplement for Alzheimer’s prevention. Anyone evaluating a product that claims to protect cognition should ask whether a randomized trial supports the claim. If the answer is no, skepticism is warranted.
Long-range projections for Alzheimer’s prevalence also carry significant uncertainty. Some models suggest the affected population could nearly triple by 2050, but the exact trajectory depends on demographic shifts, the uptake of new treatments, and whether prevention strategies gain real traction at the population level. Different studies use different baselines, so any single number decades out should be treated as an estimate, not a guarantee.
The weight carried by caregivers
Alzheimer’s does not only affect the person who carries the diagnosis. More than 11 million Americans currently provide unpaid care to someone with Alzheimer’s or another form of dementia, according to the Alzheimer’s Association. Those caregivers face elevated rates of depression, financial strain, and their own physical health problems. Many are juggling full-time jobs, raising children, and managing complex medical decisions with little formal support.
The CDC’s Alzheimer’s Disease Program lists caregiving support as one of its three national priorities, alongside risk reduction and data surveillance. But federal tracking of caregiver outcomes remains limited, and the gap between stated priorities and on-the-ground resources is something families feel acutely. Respite care programs are underfunded in many states. Workplace flexibility policies vary wildly. And clear, trustworthy guidance on navigating the caregiving journey is harder to find than it should be.
As the U.S. population ages and more Americans live longer with dementia, how the country supports caregivers will shape whether the burden of Alzheimer’s falls on isolated households or is shared more equitably across communities and systems.
What doctors want people to do now
The practical message from federal agencies and leading researchers has converged on a short, actionable list: control blood pressure aggressively, stay physically active, manage cardiovascular risk factors like diabetes and high cholesterol, maintain social connections, and protect your hearing. These steps will not guarantee that someone avoids Alzheimer’s. But they represent the best tools available today, backed by the strongest evidence science has produced so far.
With 7 million Americans already living with the disease and that number expected to rise, the window for prevention is not theoretical. It is open right now, and doctors say the time to act is before symptoms ever appear.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
